Kornimate/medical-research-clean huggingface dataset:
predictive value of cardiovascular magnetic resonance related parameters in stemi patients after primary pci for adverse left ventricular remodeling and major adverse cardiovascular events

Conditions: Cardiovascular Diseases

Summary: this study aim to investigate the predictive value of cmr parameters: infarct size (is), intramyocardial hemorrhage, microvascular obstruction, area at risk and cmr derived strain parameters with the major adverse cardiovascular events (maces) and myocardial remodeling afterinfarction.

investigators will enroll 500 patients with stemi after pci who were admitted to the chinese pla general hospital and other eight hospitals across china: wuhan asia heart hospital; the first people's hospital of yunlin; chaoyang hospital, capital medical university; hainan hospital of pla general hospital; the second affiliated hospital of nanchang university; the second hospital of hebei medical university; guizhou provincial people's hospital; affiliated hospital of zunyi medical college between january 2014 and december 2019. cmr was performed at 7 days and 6 months after primary pci to assess the final infarction size(is), microvascular obstruction (mvo), intramyocardial hemorrhage(imh), area at risk (aar) and related strain parameters. all patients will be followed up by 5 years after adimission. cardiovascular events concluded stroke, repeat revascularization, rehospitalization for acute heart failure, nonfatal myocardial infarction, and all cause death. all adverse clinical events as well as study end points were monitored and adjudicated by the independent event committee.

Eligibility criteria:
inclusion criteria: 1. age 18-80 years. 2. clinically diagnosed st-segment elevation myocardial infarction. 3. intended to undergo emergency pci. 4. voluntary enrollment and signed informed consent form. exclusion criteria: 1. undergoing revascularization (pci or coronary artery bypass grafting (cabg)) within 6 months; 2. pregnant and breastfeeding women; 3. contraindications of cmr: implanted cardiac defibrillator (icd), claustrophobia, allergy to gadolinium 4. liver or kidney failure; 5. malignant tumor; 6. unconscious at present; 7. systolic blood pressure (sbp) less than 80 mmhg; 8. patients with bundle branch or fascicular block, insufficient ecg data. 9. patients with other significant abnormal signs, laboratory tests and clinical disease are unsuitable for participation in the study accessed by clinicians.

Keywords: intramyocardial hemorrhage(imh) microvascular obstruction(mvo) area at risk(aar) cmr related strain st-segment elevation myocardial
a study to explore hereditary angioedema (hae) symptoms and treatment patterns in korean people

Conditions: Hereditary Angioedema (HAE)

Summary: this study intends to gather information on hae attack symptoms, how often the attacks occur, and the number of times treatment is required to manage the attacks in korean people over a period of up to 11 months. the main aims of this study are the following: * to describe the patterns of hae attacks, including how often they occur, where they happen in the body, how severe they are, the time between attacks, and any warning signs that appear before an attack. * to assess how hae is treated, particularly looking at how on-demand treatments are used during hae attacks. * to learn about the people who suffer from hae attacks (e.g. age, gender, for how long they have been suffering from hae, and if they use danazol to manage hae). in this study, already existing data will be collected and reviewed from a mobile application called "myhae story". the study will only review data collected as part of the clinical routine practice. the study will not impact the standard medical care and treatment of participants.


Eligibility criteria:
inclusion criteria: * participants who are participants in the onheart psp program. * participants who have registered in "myhae story" mobile application. exclusion criteria: - participants who neither have made input to at least one attack nor have run the app by clicking 'myhae story' tab within the kakaotalk chat message at least once after app registration.

Keywords: drug therapy
the effect of 5 times dry cupping in the treatment of chronic neck pain

Conditions: Neck Pain; Neck Pain Musculoskeletal; Mechanical/Motor Problems With Neck and Trunk

Summary: the study aims to investigate the influence of 5 dry cupping treatments on chronic non specific neck pain. 50 patients with neck pain are randomised into cupping treatment and waiting list control group at t0 (day 0). at t1 (day 7)the investigators evaluate the neck pain (vas), the neck related disability (ndi), pain related to movement (prtm) and the quality of life (sf36). to investigate neurophysiological effects of cupping we also measure mechanical detection threshold (mdt), vibration detection threshold (vdt) and pressure pain threshold (ppt) at pain related and control areas. the treatment group then receives 5 cupping treatments over a period of two weeks. after the cupping series resp. a waiting period for the waiting list control group (t2, day 25) all measurements from t1 are repeated (vas, ndi, prtm, sf36, mdt, ppt, vdt). at last, a pain and medication diary is filled in by the patients from t0(day 0) until t2 (day 25). the investigators hypothesize, that cupping treatment is effective against neck pain (diary, vas, ndi, prtm, sf36) and that it leads to changes on perceptual level (mdt, vdt, ppt), when compared to the waiting list control group.

see above

Eligibility criteria:
inclusion criteria: * age between 18 and 75 * permanent neck pain for at least three months in a row * a minimum of 40mm of neck pain on a 100mm visual analogue scale (vas) * having been in treatment to an orthopaedic or to a neurologist exclusion criteria: * neck pain caused by trauma, inflammatory or malignant disease, by congenital malformation of the spine or if pain was accompanied by radicular symptoms such as radiating pain, paresis, prickling or tingling. * invasive treatments within the last 4 weeks, surgery to the spine within the last year, corticosteroid or opioid treatment. * serious acute or chronic organic disease such as diabetes or cancer, mental disorders, pregnancy, and haemorrhagic tendency or anticoagulation treatment. * non steroidal pain medication and physiotherapy were allowed if the treatment regimen was not altered for four weeks before and continued during the study.
a study comparing the efficacy and safety of valdecoxib plus parecoxib versus valdecoxib plus placebo for the treatment of pain after coronary artery bypass surgery

Conditions: Pain

Summary: the purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery


Eligibility criteria:
inclusion criteria: * patients expected to receive in-hospital pain medication for pain after coronary artery bypass graft surgery for at least 3 full days and pain medication over a 10-day period * new york heart association class i to iii or cardiac ejection fraction of at least 35% before surgery * body mass index of less than or equal to 40 kg/m2 and weight of \>55 kg * patients scheduled to undergo an isolated (bypass grafting only without valve replacement, significant aortic reconstruction, or ventriculoplasty) primary cabg surgery via median sternotomy, using cardiopulmonary bypass exclusion criteria: * patient has undergone or is going to have emergency coronary artery bypass graft surgery or surgery without cardiopulmonary bypass procedure * symptomatic peripheral vascular disease * heart attack within 48 hours of surgery
inpatient multimodal path to recovery

Conditions: Pain; Opioid Use

Summary: the goal of the proposed study is to develop and implement a comprehensive strategy to address pain management in the inpatient setting while appropriately managing pain and optimizing patient safety in the inpatient setting. this strategy involves developing a new health information technology tool in the omnicell and electronic medical record, implementing a "menu" of pain management and relaxation strategies, and developing educational materials for staff and patients to change the culture of pain management.

the goal of the proposed study is to develop and implement a comprehensive strategy to address pain management in the inpatient setting while appropriately managing pain and optimizing patient safety in the inpatient setting. this strategy involves developing a new health information technology tool in the omnicell and electronic medical record, implementing a "menu" of pain management and relaxation strategies, and developing educational materials for staff and patients to change the culture of pain management. this intervention will be implemented throughout chs hospitals, using a stepped wedge design to guide rollout. the initial pilot will be conducted in the trauma inpatient units at carolinas medical center. all patients admitted to the two primary trauma units (11a and 11 tower) during the pilot study period will be included in the evaluation.

Eligibility criteria:
inclusion criteria: * all patients treated in facility as inpatient during the study period will be included in the analysis. exclusion criteria: * patients not admitted to facility during the study period will be excluded from the analysis.

Keywords: opioid inpatient pain multimodal
escape study : validation of a specific tool scoring residents at risk of escaping/elopement from nursing homes (escape)

Conditions: Elopement or Escaping of Nursing Home Resident With or Without Dementia

Summary: residents' escapes occur even if most of the nursing homes (nh) have set up specific devices to prevent from this risk. therefore, the need to develop and validate a specific tool to assess the risk of escaping was obvious to the working group, aim at emphasizing patient centered-care by the nurses' staff and help to develop personalized devices. aim of the study: develop and validate a specific tool to score the risk of escaping in nh residents study design: observational prospective multicentered cohort study nursing homes volunteer to participate location: provence alpes cotes d'azur region ( south east of france) population: 4050 nh residents. duration: two years, each resident included is followed up for one year measures: nursing homes characteristics, residents characteristics ( social and from medical record); escape scale (25 items with a yes/no answer; filled up during a nurses staff meeting for each resident and every three months; 3 sub scales: resident environmental items, social items, and medical items.


Eligibility criteria:
inclusion criteria: * every resident of nursing home participating to the study * living in the nh for three months or more * with a living prognosis longer than 3 months exclusion criteria: * prognosis less than three months * bedridden (not able to move alone from bed to chair) * nursing home short stay scheduled \< 3 months
evaluate time associated with the preparation & administration of denosumab/pamidronate in patients with solid tumors and metastatic bone disease

Conditions: Solid Tumor; Metastatic Bone Disease

Summary: this study will estimate the total time for the preparation and administration of denosumab and the total time for the preparation and administration of pamidronate.


Eligibility criteria:
inclusion criteria: * diagnosis of metastatic bone disease secondary to a solid tumor (eg, breast cancer, lung cancer, etc). * an eastern cooperative oncology group (ecog) performance status of 0 or 1. * subject is one of the following: * being considered for pamidronate iv infusions or denosumab sc injections for treatment of metastatic bone disease (prescribed per canadian product monograph); or * scheduled to receive pamidronate iv infusions or denosumab sc injections for treatment of metastatic bone disease (prescribed per canadian product monograph); or * currently receiving pamidronate iv infusions or denosumab sc injections for treatment of metastatic bone disease and has received no more than 4 prior administration of either product combined (prescribed per canadian product monograph). * subject has a serum calcium or albumin-adjusted serum calcium ≥ 2.0 mmol/l (8.0 mg/dl) and ≤ 2.9 mmol/l (11.5 mg/dl) exclusion criteria: * diagnosis with metastatic bone disease secondary to multiple myeloma or prostate cancer. * severe renal impairment (creatinine clearance \< 30 ml/min) * subject is being considered for ambulatory pamidronate administration using an infuser device (ie, "baby bottle"). * a known active infection with hepatitis b virus or hepatitis c virus. * subject has known positive results for human immunodeficiency virus (hiv).subject has a history of other malignancy within the past 5 years, other than: * malignancy treated with curative intent and with no known active disease present for ≥ 5 years before enrollment and felt to be at low risk for recurrence by the treating physician * adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * adequately treated cervical carcinoma in situ without evidence of disease * adequately treated breast ductal carcinoma in situ without evidence of disease * prostatic intraepithelial neoplasia without evidence of prostate cancer * adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ. * subject has a history or current evidence of osteonecrosis/osteomyelitis of the jaw, active dental or jaw condition that requires oral surgery, non-healed dental/oral surgery, or planned invasive dental procedure over the course of the study.
safety, tolerability, pharmacokinetics, and pharmacodynamics of isis 702843 administered subcutaneously to healthy volunteers

Conditions: Thalassemia

Summary: the purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ionis tmprss6-lrx administered subcutaneously for up to 44 healthy volunteers


Eligibility criteria:
inclusion criteria: * must have given written informed consent and be able to comply with all study requirements * healthy males or females aged 18-65 inclusive at the time of informed consent * females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal * males must be surgically sterile, abstinent or using an acceptable contraceptive method * bmi \< 32 kg/m2 exclusion criteria: * clinically significant abnormalities in medical history or physical examination * clinically significant lab abnormalities that would render a subject unsuitable for inclusion * known history or positive test for hiv, hcv, or hbv * treatment with another study drug, biological agent, or device within one-month of screening or 5 half-lives of investigational agent, whichever is longer * smoking \> 10 cigarettes per day * regular excessive use of alcohol within 6 months of screening * current use of concomitant medications other than occasional acetaminophen (paracetamol) or ibuprofen unless approved by sponsor medical monitor * considered unsuitable for inclusion by the investigator or sponsor

Keywords: thalassaemia, ionis tmprss6-lrx
remission of lumbar disc herniation by physiotherapy

Conditions: Lumbar Disc Herniation

Summary: this study was conducted with the aim of determining whether or not non surgical spinal decompression therapy was effective in remission of herniation, decreasing pain and improving functional status.

both groups received combination of electrotherapy, deep friction massage and stabilization exercise for fifteen session. combine group received non surgical spinal decompression therapy (nsdt) different from conventional physiotherapy group. numeric analog scale, straight leg raise (slr) test, oswestry disability index (odi) were applied at baseline and after treatment. disc height and herniation thickness were measured on magnetic resonance imagination (mri) which performed at baseline and three months after therapy.

Eligibility criteria:
inclusion criteria: diagnosed as lumbar disc herniation suffering from low back pain at least 8 weeks exclusion criteria: undergone any spinal surgery clinical diagnosis of osteoporosis clinical diagnosis of scoliosis and spondylolisthesis any neurological disease causes sensorial loss

Keywords: non surgical spinal decompression therapy deep friction massage exercise
study to assess the safety, pharmacokinetics, and efficacy of baloxavir marboxil in healthy pediatric participants from birth to < 1 year with influenza-like symptoms

Conditions: Influenza

Summary: this study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to \<1 year with influenza like symptoms


Eligibility criteria:
inclusion criteria: * age from birth to \< 1 year at screening * written informed consent for study participation obtained from participant's parents or legal guardian * parent/guardian willing and able to comply with study requirements, in the investigator's judgment * participants with a diagnosis of influenza virus infection confirmed by the presence of all of the following: 1. in the investigator's judgement there is a clinical suspicion of influenza 2. at least one respiratory symptom (either cough or coryza) (b) positive prescreening influenza test (ridt or pcr) performed within 48 hours of screening * participants with a negative prescreening covid-19 test (rat or pcr) within 48 hours of screening * the time interval between the onset of symptoms and screening is ≤ 96 hours (the onset of symptoms is defined as the time when body temperature first exceeded 37.5°c if known, or the time when the first symptom was noticed by the parent or caregiver) exclusion criteria: * hospitalized for complications of influenza or significant comorbidities * concurrent infections requiring systemic antiviral therapy at screening * require, in the opinion of the investigator, any of the prohibited medication during the study * preterm neonates (born at \< 37 weeks gestation) and/or weighing \< 2.5 kg at screening * previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine within 2 weeks prior to screening * immunization with a live/attenuated influenza vaccine during the 2 weeks prior to screening * concomitant treatment with steroids or other immuno-suppressant therapy * known hiv infection or other immunosuppressive disorder * uncontrolled renal, vascular, neurologic or metabolic disease (e.g., diabetes, thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or participants with known chronic renal failure * active cancer at any site * history of organ transplant * known hypersensitivity to study drug (i.e., baloxavir marboxil) or to acetaminophen * participation in a clinical trial within 4 weeks or five half-lives of exposure to an investigational drug prior to screening, whichever is longer
a safety study of stsp-0601 in adult patients with hemophilia a or b with inhibitor

Conditions: Hemophilia

Summary: this study will assess the pharmacokinetics and pharmacodynamics of stsp-0601 at six dose levels. the results will help identify the most optimal doses to treat bleedings in hemophilia patients with inhibitors.


Eligibility criteria:
inclusion criteria: * 18 years old ≤age≤65 years of age,male. * hemophilia a or b patients with inhibitors. * peak historical inhibitor titer ≥ 5 bu and a positive inhibitor test when enrolled. * establish proper venous access. * provide signed informed consent. exclusion criteria: * have any coagulation disorder other than hemophilia a or b. * treat with prophylactic treatment of coagulation factor. * treat with anticoagulant within 7d of the time of study drug administration. * have an active, ongoing bleeding for which the patient is being treated, or treatment for a bleeding was stopped within 7d of the time of study drug administration. * have a history of arterial and/or venous thromboembolic events. * have platelet count \<100,000/ml. * severe liver or kidney disease. * accept major operation or blood transfusion within 1 month of the time of screening. * hiv antibody positive. * have a known allergy to blood product. * participate in other clinical research within 1 month of the time of study drug administration.
influence of therapeutic education in patients with joint inflammation treated with a biological treatment

Conditions: Non-radiographic Spondyloarthritis

Summary: to describe, with a patient reported score (biosecure), the influence of an approved therapeutic education program (tep) in patients with joint inflammation requiring a biological treatment initiation. the hypothesis is that patients attending the tep will display better cognitive and adaptation competences than patients with no tep. patient's reported quality of life, disease related stress management, treatment adherence, socio-demographic factors, biological home administration modalities and if the biologic treatment is maintained at 12 months, will also be described.


Eligibility criteria:
inclusion criteria: * non-radiological spondyloarthritis diagnosis (asas criteria) * anti-tnfalpha biological treatment initiation required * adult patient (age\>18years) * capacity to understand self-questionnaires and address questions * patient accepting to attend a therapeutic education program (tep) exclusion criteria: * previous anti-tnfalpha biological treatment * previous attendance to a tep concerning biological or spondyloarthritis * contraindication to anti-tnfalpha treatment * associated and unbalanced diseases

Keywords: therapeutic education
feasibility and safety of a single working element for bipolar and laser enucleation in prostate surgery: a prospective study

Conditions: Prostate; BPH (Benign Prostatic Hyperplasia)

Summary: a prospective feasibility study would be a practical first step, focusing on real-time assessment and ensuring the new working element's integration is safe and effective before broader clinical trials.


Eligibility criteria:
inclusion criteria: * diagnosed with benign prostatic hyperplasia (bph) requiring surgical intervention. * prostate volume ≥40 cc (as assessed by transrectal ultrasound). * no prior history of prostate cancer. exclusion criteria: * patients with ongoing urinary tract infections. * prior prostate surgeries. * coagulation disorders or patients on long-term anticoagulation therapy. * known urethral strictures or other anatomical abnormalities complicating endoscopic procedures.

Keywords: laser enucleation bipolar enucleation bph prostate
circuit training and aerobic exercise among sedentary elderly population

Conditions: Sedentary Behavior; Old Age; Debility

Summary: to compare the effects of circuit training and aerobic exercise on cardiopulmonary fitness among sedentary elderly population


Eligibility criteria:
inclusion criteria: * participants meeting the below criteria, shall be recruited in the study. * sedentary elderly people (can perform 6 mwt without complication) * sedentary elderly population * no regular exercise or gym activity since last 6 months exclusion criteria: * already trained (any gym activity or regular exercise) * diagnosed cardiopulmonary disease * diabetes * any neurological complication

Keywords: aerobic exercise circuit training